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It is now well-known that the enhanced expression of ATP binding cassette (ABC) and
major facilitator superfamily (MFS) proteins contribute to the development of tolerance to
antifungals in yeasts. For example, the azole resistant clinical isolates of the opportunistic
human fungal pathogen Candida albicans show an overexpression of Cdr1p and/or
CaMdr1p belonging to ABC and MFS superfamilies, respectively. Hence, azole resistant
isolates display reduced accumulation of therapeutic drug due to its rapid extrusion and
that facilitates its survival. Considering the importance of major antifungal transporters,
the focus of recent research has been to understand the structure and function of these
proteins to design inhibitors/modulators to block the pump protein activity so that the
drug already in use could again sensitize resistant yeast cells. The review focuses on the
structure and function of ABC and MFS transporters of Candida to highlight the recent
advancement in the field.
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INTRODUCTION
The occurrence of fungal infections has risen dramatically
over the past few decades because of the increase in number
of immunocompromised patients undergoing, transplantation
surgery, cancer chemotherapy and having an HIV infection etc.
(Richardson, 2005). The severity of fungal infections varies from
superficial to life-threatening systemic infections. When fungi
penetrate the epithelial surfaces of immunocompromised hosts
they cause invasive fungal infections that are associated with high
morbidity and mortality. The fungal genera most often associ-
ated with invasive fungal infections include Candida, Aspergillus
and Cryptococcus (Pfaller and Diekema, 2007). The opportunistic
C. albicans accounts for approximately 50–60% causes of candidi-
asis particularly in immunocompromised patients. Superficial
infections caused by C. albicans are commonly treated with azole
drugs while life-threatening systemic infections are treated with
triazole drugs, or the more recent and expensive echinocandins
(Perlin, 2011).
The widespread and prolonged use of antifungals results
not only in the development of tolerance toward the not only
drug in use, but also in the development of collateral resis-
tance to other drugs and to a variety of unrelated compounds
(Figure 1). The development of resistance to a variety of unre-
lated compounds is termed as multidrug resistance (MDR).
The clinical emergence of MDR is common occurrence which
poses a major hurdle in antifungal therapy. Notably, MDR is
not restricted to fungi but it is a wide occurrence phenom-
ena observed in various organisms throughout the evolutionary
scale. Combating MDR poses major challenge to clinicians since
Abbreviations: P-gp, P-glycoprotein; ABC, ATP binding cassette; MFS, major
facilitator superfamily; MDR, multidrug resistance; PDR, pleiotropic drug resis-
tance; NBD, nucleotide binding domain; TMD, transmembrane domain; TMS,
transmembrane segments; ECLs, extracellular loops; ICL, intracellular loops; CCL,
central cytoplasmic loop.
it is also a multi-factorial phenomenon where a combination
of mechanisms could contribute in the development of drug
tolerance. The several mechanisms of MDR which have been
characterized in yeast, includes the development of Candida cell’s
inability to accumulate drugs intracellularly to toxic levels due
to an overexpression of membrane-associated transporters acting
as multidrug efflux pumps. The rapid efflux in resistant strains
ensures that the drug is not accumulated to lethal levels. Several
azole-resistant clinical isolates of C. albicans as well as of other
fungal pathogens like Aspergillus fumigates and Cryptococcus neo-
formans display transcriptional activation of efflux pump encod-
ing genes and often show reduced intracellular accumulation
of drugs, thus confirming the role of efflux proteins in drug
extrusion and tolerance (Prasad et al., 2002).
There are two main classes of transport proteins which are
mainly responsible for the development of antifungal resistance,
involving different mechanistic strategies to efflux drugs. For
example, while superfamily of ATP-binding cassette (ABC) pro-
teins are primary active transporters that employ energy from the
hydrolysis of ATP to drive the efflux of drugs, those belonging to
major facilitator superfamily (MFS) are secondary active trans-
porters that utilize the electrochemical gradient of protons across
the plasma membrane to efflux substrates (Cannon et al., 2009).
Both classes of pumps are integral membrane proteins with dis-
tinctive functional domains. Because of the importance of drug
transporters in MDR, there has been a spurt in research on all
aspects of these transporters. In this review, we update studies on
the structure and function of these transporters particularly those
belonging to C. albicans.
ABC PROTEINS IN CANDIDA
The release of the genome sequence of the diploid human
pathogenic fungus C. albicans made it possible to analyse the
superfamily of ABC proteins (Braun et al., 2005). The genome
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FIGURE 1 | Venn diagram showing substrates which are common and distinct for Cdr1p and CaMdr1p.
wide inventory of C. albicans reveals that it has 28 putative
ABC proteins including 12 half transporters that remain unchar-
acterized (Gaur et al., 2005). By employing neighbor-joining
tree and self-organizing-map-based clustering methods, these 28
putative ABC proteins can be grouped into five known sub-
families: PDR (pleiotropic drug resistance), MDR (multidrug
resistance), MRP (multidrug resistance-associated protein), RLI
(RNase L inhibitor)/ALDP (adrenoleukodystrophy protein), and
YEF3 (yeast elongation factor EF-3), and a sixth “others” cate-
gory that includes soluble (Table 1) ABC non-transporter pro-
teins unrelated to the existing fungal subfamilies. The PDR
protein subfamily of C. albicans comprises seven full-sized
members: Cdr1p (Prasad et al., 1995), Cdr2p (Sanglard et al.,
1997), Cdr3p (Balan et al., 1997), Cdr4p (Franz et al., 1998),
Cdr11p (Ca918, assembly #20 http://www.candidagenome.org/
download/Assembly20notes/), CaSnq2p, and Ca4531 (Gaur et al.,
2005). However, only two proteins of PDR subfamily viz Cdr1p
and Cdr2p have been shown to be multidrug transporters (Prasad
et al., 1995; Sanglard et al., 1997). The other well characterized
close homologs such as Cdr3p and Cdr4p are not drug trans-
porters but are involved in phospholipids translocation within the
lipid bilayer of natural membrane.
The Cdr1p represents a major drug transporter of C. albicans
and an overexpression of its encoding gene is directly associ-
ated with an increased drug substrate efflux in azole resistant
clinical isolates recovered from patients receiving long term anti-
fungal therapy (Prasad and Goffeau, 2012). Over the years, Cdr1p
thus has acquired significant clinical importance and consider-
able attention is rightly being paid in understanding the struc-
tural and functional aspects of this protein. It is expected that
such a structural and functional approach could lead to bet-
ter strategies for designing modulators/inhibitors of this pump
enabling combating of antifungal resistance. Cdr1p is an integral
plasma membrane protein of 1501 amino acids, with a predicted
molecular weight of 169.9 kDa (Prasad and Goffeau, 2012). It is
organized as two homologous halves representing reverse topol-
ogy (NBD-TMD)2 as compared to human ABC transporter P-gp.
Each half begins with a cytoplasmic hydrophilic nucleotide bind-
ing domain (NBD) followed by a highly hydrophobic transmem-
brane domain (TMD) (Figure 2). Each TMD comprises α-helices
of six TMS (transmembrane segments), which creates the sub-
strate promiscuity in the protein (Krishnamurthy et al., 1998a;
Puri et al., 2010; Prasad et al., 2011). The NBDs bind and hydrol-
yse the ATP to drive drug efflux. Conformational changes induced
by ATP binding and/hydrolysis are transmitted from the NBDs to
the TMDs, which can result in drug translocation, drug efflux or
resetting of the reaction cycle.
TRANSMEMBRANE DOMAINS FORM PROMISCUOUS DRUG BINDING
SITE
Despite the overall conservation of the domain architecture of
TMDs, their primary sequences are variable among similar trans-
porters. Thus, the extent of conservation is very poor among
TMSs of fungal ABC transporters as compared to NBDs which
are highly conserved domains (discussed later). The promiscu-
ity toward substrates is a characteristic feature of most ABC
drug transporters and hence makes their functionality all the
more complex to understand. Therefore, considerable attention
is being devoted toward assessment of the structural and func-
tional features in Cdr1p which could explain its diverse sub-
strate specificity spectrum. Understanding the structure activity
relationship (SAR) between drug transporter protein and host
of xenobiotics they export is expected to improve therapeutic
strategies. For this, already there have been concerted efforts to
understand the basis of promiscuity ofmultidrug resistance trans-
porters. Several studies have been undertaken to identify the drug
binding site(s) to elucidate the molecular attributes required for
substrate/transporter interactions as described below.
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Table 1 | ABC transporters of Candida albicans.
Subfamilya ORF names Gene name Sizeb Location Topologyc Function References
PDR CaO19.6000 CaCDR1 1501 PM (NBD-TMS6)2 Drug effIux, phospholipid
translocation
Prasad et al., 1995
CaO19.5958 CaCDR2 1499 PM (NBD-TMS6)2 Drug effIux, phospholipid
translocation
Sanglard et al., 1997
CaOI9.1312 CaCDR3 1501 PM (NBD-TMS6)2 Opaque-phase specific
transporter, phospholipid
translocation
Balan et al., 1997;
Smriti et al., 2002
CaO19.5079 CaCDR4 1490 ND (NBD-TMS6)2 Phospholipid
translocation
Franz et al., 1998
CaO19.918 CaCDR99 683 ND NBD-TMS6 Drug efflux pump Gaur et al., 2005
CaO19.919 819 ND NBD-TMS6 ND Gaur et al., 2005
CaO19.5759 1493 ND (NBD-TMS6)2 ND Gaur et al., 2005
CaO19.4531 1245 ND (NBD-TMS6)2 ND Gaur et al., 2005
CaO19.3120 584 ND NBD-TMS6 ND Gaur et al., 2005
CaO19.459 719 ND TMS1-NBD-TMS7 ND Gaur et al., 2005
MDR CaO19.7440 CaHST6 1328 ND (TMS6-NBD)2 Transport of α-factor,
drugs
Raymond et al., 1998
CaO19.2615 CaMDL1 659 ND TMS6-NBD ND Gaur et al., 2005
CaOI9.13043 726 ND TMS6-NBD ND Gaur et al., 2005
CaOI9.1077 730 ND TMS6-NBD ND Gaur et al., 2005
MRP/CFTR CaO19.6478 CaYOR1 711 PM TMS6-NBD Drug efflux pump Gaur et al., 2005
CaO19.1783 CaYCF1 1512 Vacoule (TMS6-NBD)2 Drug efflux pump Gaur et al., 2005
CaO19.5100 CaMLT1 1544 Vacoule (TMS6-NBD)2 Transport involved in
virulence
Theiss et al., 2002
CaO19.6382 1254 ND (TMS6-NBD)2 ND Gaur et al., 2005
CaO19.1784 763 ND TMS6-NBD ND Gaur et al., 2005
ALDp CaO19.7500 652 ND TMS6-NBD ND Gaur et al., 2005
CaO19.5255 615 ND TMS6-NBD ND Gaur et al., 2005
EF3 CaO19.6060 751 ND NBD-NBD ND Gaur et al., 2005
CaO19.2183 585 ND NBD-NBD ND Gaur et al., 2005
CaO19.7332 CaELF1 1097 ND NBD-NBD M-RNA export factor Sturtevant et al., 1998
CaO19.4152 CaCEF3 978 ND NBD-NBD ND Myers et al., 1992
RLI CaO19.3034 602 ND NBD-NBD ND Gaur et al., 2005
Others CaO19.5029 545 ND NBD-NBD ND Gaur et al., 2005
CaO19.388 276 ND NBD ND Gaur et al., 2005
asubfamily based on sequence similarity with human ABC transporters.
bNumber of amino acid residues.
cNBD, nucleotide-binding domains; TMS, transmembrane segments.
ND, signifies not defined.
The mechanisms of substrate interaction with proteins pos-
sessing multiple TMDs are difficult to assess directly because of
the absence of crystal structure of these proteins. It is, there-
fore desirable to take advantage of computational techniques
such as three dimensional quantitative structure-activity rela-
tionships (3D-QSAR). Identifying the characteristic molecular
descriptors is a prerequisite for these computational modeling
approaches which have been successfully used in case of human
ortholog of the organic cation transporter (hOCT1). The work
on Pdr5p of Saccharomyces cerevisiae, a close homologous pro-
tein of Cdr1p, has offered significant information about the
requirement of substrate binding sites. The study by Golin et al.
(2000) concluded that hydrophobicity and anion makeup a rela-
tively unimportant factors in determining whether a tri-n-alkyltin
compound isa good Pdr5p substrate. However, dissociation of the
compound and the molecular size appeared to be an important
issue. Although a great deal of similar research has been devoted
to the investigation of Cdr1p, still the chemical basis of sub-
strate recognition and transport of these promiscuous trans-
porters of pathogenic C. albicans remains speculative. A recent
study provided an insight into the physico-chemical basis of
substrate specificity of Cdr1p. For this, several compounds of
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FIGURE 2 | Schematic representation of the predicted topology of
Cdr1p. Cdr1p is predicted to have two transmembrane domains
(TMD1 and TMD2) and two NBDs, (N- and C-terminal NBDs)
organized in reverse (NBD-TMS6)2 topology. The amino and carboxyl
terminals of protein are indicated. Each TMD consists of six TMSs,
which are numbered 1–6 in TMD1 and 7–12 in TMD2. Six
extracellular loops (ECL1-6) and four intracellular loops (ICL1-4) are
indicated.
diverse character were randomly selected and screened for their
increased toxicity to S. cerevisiae strains over-expressing Cdr1p
(Puri et al., 2010). On the basis of SAR of substrates and non-
substrates, it was observed that, the substrates of Cdr1p had
higher hydrophobicity index. The molecular descriptors used in
that study further demonstrated that high aromaticity, molecular
branching and occurrence of atom centered fragment (ReCHeR)
to be the general prerequisites of compounds which are substrates
of Cdr1p.
Understanding, how transport protein recognizes such diverse
nature of substrate remains a challenge. In an effort to understand
the molecular basis of drug recognition, binding and release,
several studies have been done to elucidate the location and bio-
physical properties of the drug-binding sites in Cdr1p. One such
study, characterized, three drug binding sites in Cdr1p, one for
the binding of rhodamine 6G and azoles such as ketaconazole,
miconazole, and itraconazole, second for only fluconazole and
third site for iodoarylazido prazosin (IAAP, a photoaffinity analog
of the P-gp substrate prazosine, whose binding could be out-
competed by Cdr1p substrate nystatin) (Shukla et al., 2003; Puri
et al., 2009). Following extensive site directed mutagenesis of
TMS regions of Cdr1p, the role of few TMSs and amino acid
residues in in drug transport has been described. For example,
the alanine scanningmutagenesis of TMS11 where all the residues
were individually replaced with alanine, not only highlighted that
Thr1351 of TMS11 of Cdr1p is involved in substrate transport
as well as loss of inhibition by FK520, a well known modula-
tor of Cdr1p, but also shed significant light on the role of the
entire TMS11. Mutations N1348A, N1359A, L1353A, C1361A,
T1351S, and T1355S had no effect on any substrate tested. In con-
trast, T1355F and F1360A substitution produced unique mutant
proteins that drastically lost the ability to confer drug resistance
to almost all the tested drugs. But unlike T1351F, they retained
the susceptibility to FK520 (Saini et al., 2005). The study showed
that all the polar residues of TMS11 are not involved in determin-
ing the substrate specificity. The non-conservative substitution
(Phe) of Thr resulted in an enhanced susceptibility to drugs
whereas more conservative substitution (Ser) had no effect The
elimination of the aromatic side chain of Phe1360 decreased the
resistance to several fold for all the tested drugs. Together, the
study strongly implicated the role of select residues of TMS11 in
the mechanism of Cdr1p drug recognition and efflux.
A more recent study probed the nature of drug binding pocket
of Cdr1p by performing alanine scanning mutagenesis of the
entire primary sequences of the two TMDs, wherein, each of
the 252 residues (found in 12 TMSs) replaced with an alanine
(Rawal et al., 2013). The study identified several of the replace-
ments to be critical based on the fact that almost all TMSs that,
upon mutation, abolished resistance to all drugs tested singly or
in combinations (Figure 3) and were predominantly restricted
to the non-lipid-facing surface, consistent with close proximity
to the substrate-binding pocket. Lipid bilayer-facing surfaces on
each TMS of Cdr1p were identified using the empirical scor-
ing function LIPS (LIPid-facing surface), which is based on the
lipophilicity and conservation of residues in the helix (Rawal
et al., 2013). Residues with high LIPS score (red curves in pep-
wheels in Figure 3) are expected to face a lipid environment
while, the low scoring non-LIPS residues face the substrate-
binding site and their substitution is more likely to affect the
drug sensitivity of cells over-expressing Cdr1p. Functional data
and homology modeling of Cdr1p revealed multiple overlapping
mini drug-binding sites within a large centrally located polyspe-
cific drug binding pocket, wherein, all the TMSs, apart from
TMS4 and TMS10, interact directly with the drug-binding cav-
ity. The presence of multiple drug binding sites with different
requirements for substrate-transporter interaction accounts for
the wide variety of substrates known to interact with Cdr1p
(Figure 1). The critical residues were found to be predominantly
clustered on TMS1, TMS2, and TMS11 on one side of Cdr1
structure and TMS4, TMS5, and TMS8 on another side, while
TMS3, TMS6, TMS7, TMS9, and TMS10 contribute relatively
fewer such residues. The 3D deduced homology model of Cdr1p
also revealed that the amino acid residues that bordered a drug-
binding cavity dominated by hydrophobic residues, which is in
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FIGURE 3 | A list of residues from Cdr1p that upon substitution gave a
phenotype. The color gradient of individual TMS in the central Cdr1p cartoon
shows the relative transmembrane conservation based on conservation
scores obtained from JALVIEW2.4.0.b2 (Rawal et al., 2013). A red color
indicates the highest conservation score while yellow indicates the lowest
score. Abbreviations: MUT (mutants), P (phenotype), TS (susceptible to all
drugs), SS (selectively susceptible), ECL (extracellular loop), NBD
(nucleotide-binding domain), TMS (transmembrane segments). Below each
table are the pepwheels showing LIPS (LIPid-facing Surface) residues. Helical
wheel projections of each TMS sequence were constructed using http://rzlab.
ucr.edu/scripts/wheel/wheel.cgi (Rawal et al., 2013). The sequences are
displayed in a helical representation as if looking down the axis of the helix.
The mutations that affected drug resistance are circled pink. The red curve on
each wheel marks the location of the LIPS surface.
consistent with Cdr1p having greater affinity toward hydrophobic
rather than hydrophilic drugs. Interestingly, no direct correlation
was found between the critical residues whose replacement leads
to drug susceptibility and the conservation of TMS or the
conservation of the residues (Rawal et al., 2013).
NUCLEOTIDE BINDING DOMAINS ARE THE POWERHOUSE OF THE
PROTEIN
Although several TMSs associate together to form the drug bind-
ing cavity of Cdr1p, binding of drug alone is not sufficient for
its transport across the membrane bilayer, it also requires energy
from the nucleotide hydrolysis taking place at NBDs to drive the
drug extrusion. The NBDs can be regarded as primary sites of
generation of energy for powering the efflux of drugs from the
cells. Conformational changes induced by ATP binding and/or
hydrolysis are transmitted from the NBDs to the TMDs, which
can result in drug translocation, drug efflux, or resetting of
the reaction cycle (Gupta et al., 2011). In addition to power-
house of the protein, several residues in NBDs have also been
found to alter drug specificity toward many drugs as shown in
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Figure 3 (Jha et al., 2003, 2004; Shukla et al., 2003; Rai et al.,
2005, 2006, 2008; Kumar et al., 2010; Prasad et al., 2012). The
typical feature of all yeast ABC transporters of PDR family is
that they exhibit high basal ATPase activity and that the most
commonly observed feature of drug stimulated ATPase activity
component is completely absent from yeast proteins. Cdr1p is
also no exception, and displays high basal ATPase activity. Also,
the addition of different drugs does not affect the basal activity
to any significant level. It implies that, the transporter hydrolyze
ATP which is uncoupled from substrate transport (Shukla et al.,
2006).
NBDs are highly conserved in terms of both primary struc-
ture and domain architecture as compared to TMSs of TMD1
and TMD2. The NBDs of all ABC transporters, irrespective of
their origin and nature of transport substrate, share extensive
amino acid sequence identity and the arrangement of typical
motifs that are critical for the domain’s functionality (Higgins
and Linton, 2004). For example, NBDs of ABC transporters
have a β-sheet sub-domain containing the typical Walker A and
Walker B motifs, as an essential feature of all ATP requiring
enzymes (Prasad and Goffeau, 2012), along with an α-helical sub-
domain that possesses the conserved ABC signature sequence. A
close comparison of the primary sequences of NBDs in fungal
PDR proteins reveals that Cdr1p possess unique divergent amino
acids in their well conserved motifs. For example, N-terminal
NBD (N-NBD) motifs display sequence degeneracy in their
Walker A (GRPGAGCST) and Walker B (IQCWDN) motifs,
whereas the ABC signature sequence (VSGGERKRVS) remains
conserved. In contrast, the Walker A (GASGAGKTT) and Walker
B (LLFLD) motifs of the C-terminal NBD (C-NBD) are well
conserved and its ABC signaturemotif (LNVEQRKRLT) is degen-
erated (Figure 4) (Prasad and Goffeau, 2012). The significance
of sequence degeneracy is extensively examined to understand
the significance of unique substitutions. The studies so far have
established that the unique evolutionary replacements in Cdr1p
are functionally indispensable. For example, biochemical analysis
of a purified functional N-NBD domain of Cdr1p revealed that
the divergent Cys193 of the Walker A motif is essential for ATP
hydrolysis (Jha et al., 2003). However, since this observation was
an outcome of analyses of an in vitro isolated domain, in order to
understand the significance of variant Walker A motifs of N-NBD
and C-NBD in the context of the full protein, an in vivo study was
designed, wherein the atypical Cys193 of the Walker A motif of
N-NBD (C193K) and conserved Lys901 (K901C) in the Walker A
motif of C-NBD were replaced (Jha et al., 2004). The swapping
of the cysteine and lysine residues in the Walker A between the
FIGURE 4 | (A) Schematic representation of Cdr1p, wherein N-NBD
showing degeneracy (red typeface) in conserved Walker A motif, Walker
B motif, Q loop and H loop while C-NBD showing degeneracy in
signature C. The sequences shown for each motif is from Cdr1p.
Sequences of 85 Fungal PDR transporters having topology similar to
Cdr1p (Rawal et al., 2013) have been used for the consensus panels
below the motif sequences. Sequence conservation of NBD motifs
among fungal PDR transporters is individually depicted by Sequence
logos, which are a graphical representation of an amino acid multiple
sequence alignment. Each logo consists of stacks of symbols, one stack
for each position in the sequence. The overall height of the stack
indicates the sequence conservation at that position, while the height of
symbols within the stack indicates the relative frequency of each amino
or nucleic acid at that position. (B) A highly conserved PDR subfamily
specific motif in Cdr1p which is presenting adjacent to Walker A in both
the N-NBD (M1 motif) and C-NBD (M2 motif). Sequence conservation of
both the motifs among fungal PDR transporters is individually depicted
by Sequence logos.
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two NBDs could not retain the normal ATPase function of the
native protein. This result, not only signified the crucial position-
ing of the Cys193 and Lys901 at their respective domains, but also
demonstrated that the swapping of the two residues within the
two NBDs is intolerable to the Cdr1p function. Similarly, swap-
ping of entire N-NBD with C-NBD also yielded non-functional
protein (Saini et al., 2006). Similarly, exchange of the unique
Try326, in the Walker B motif of N-NBD with alanine (W326A)
appears to be important for ATP binding and for the accompa-
nying conformational change (Rai et al., 2005). Thus, although
the mutant with W326A appears capable of ATP hydrolysis, it
does so with a much higher KM value, indicating that the dock-
ing of substrate in the binding pocket has been altered by the
mutation. The protein, however, appears capable of near-normal
drug-transport function in cells expressing the full-length protein
carrying the W326A substitution. This implies that the confor-
mational change occurring upon ATP docking cannot by itself be
responsible for the cross talk between the NBDs and the TMDs.
While the highly conserved Asp327 of N-NBD is known to be the
catalytic carboxylate in the context of other ABC transporters, in
Cdr1p it does not appear to mediate catalysis via interaction with
Mg2+, but rather is essential for ATP hydrolysis and acts as a cat-
alytic base (Rai et al., 2006). In a recent study, it has also been
suggested that not only certain conserved residues of N-NBD sig-
nature sequence (Ser304, Gly306, and Glu307) are important in
ATP hydrolysis and drug efflux but also a few divergent residues
(Asp1002 and Glu1004) of C-NBD signature motif have evolved
to be functionally relevant and are non-interchangeable (Kumar
et al., 2010).
The unique substitutions in the N-terminal NBD of fungal
transporters do not render the domain non-functional. On the
contrary, it is unequivocally shown that the N-terminal NBD of
Cdr1p and, by extension those of other fungal transporters, have
evolved so as to use their unique substitutions to perform the
task of ATP binding and hydrolysis. While it is not yet clear what
evolutionary advantage these typical sequence variations might
provide to the organisms, it is becoming more and more evident
that it has mechanistic implications for the protein. We are yet to
understand how the N-terminal NBD works in conjunction with
the C-terminal NBD to give rise to a functional drug transporter.
Does working in tandem require the ABC Signature sequence
of one NBD to participate in ATP binding by the other, as is
seen in other ABC transporters? Like in the N-terminal NBDs,
the ABC signature sequences of Cdr1p and other fungal trans-
porters too appear to have diverged away from that of other ABC
transporters. Whether this is so as to compensate for the substi-
tutions in their N-terminal NBDs or whether they have evolved a
new mechanism for coming together for ATP hydrolysis and drug
efflux, is a question worth examining.
A NEW SUB-DOMAIN IN NBDs OF Cdr1 PROTEIN
The genome wide inventory of ABC transporters of C. albicans,
also revealed a new sequence motif characteristic of each subfam-
ily of C. albicans ABC proteins. In the transporter subfamilies
viz., PDR, MDR, MRP, and ALDp, the new motif occurred in
the region between Walker A and Walker B (Figure 4B) whereas
in the non-transporter subfamilies viz., EF3 and RLI it occurred
next to Walker B (Gaur et al., 2005). Although this new motif can
be used to identify sequences from the corresponding subfamily
in other organisms, its role in the functioning of ABC proteins
remains to be assessed.
LOOPS CONNECTING TRANSMEMBRANE SEGMENTS
The 12 TMSs of yeast ABC transporters are interlinked by six
extracellular loops (ECL1-6) on extracellular face and four intra-
cellular loops (ICL1-4) on the cytosolic face of plasma membrane
(Figure 2). ECL1, 2, 4, and 5 are generally comparable in length
and shorter than other two ECLs (ECL3 and ECL6) which are
very long. ICLs have mostly conserved primary sequences com-
pared to ECLs, but are of shorter length (Lamping et al., 2010).
The structure and functional studies so far suggest that ECLs act
like gates of drug biding pocket, mostly contribute to drug speci-
ficity, while ICLs generally serve as intra-domain transmission
interface between TMDs andNBDs (Sauna et al., 2008). However,
the exact role of ECLs and ICLs in drug transport is not well
understood.
Extracellular loops
Random mutagenesis of ABC transporter Pdr5p of S. cerevisiae
led to the identification of several point mutations that caused
significant changes in drug specificity which were found to be
distributed throughout the length of Pdr5p, particularly, in the
extracellular, transmembrane or cytoplasmic regions of the trans-
porter (Egner et al., 1998). For example, Cys1427 in the ECL6
is required for proper protein assembly in the ER membrane
and/or the cell surface targeting of Pdr5p. The study also found
a double mutation T1460I/V1467I in ECL6 which severely altered
the substrates specificity of Pdr5p. Extracellular cysteine residues
from ECL6 of Cdr1p from C. albicans are highly conserved
and critical (Shukla et al., 2003). The ECLs contain conserved
sequences that may contribute to pathways used during xeno-
biotic efflux in fungi, but their form and function is poorly
understood (Lamping et al., 2010). Niimi et al have focused
ectodomains of Cdr1p by identifying and characterizing a highly
specific surface-active inhibitor of the Cdr1p drug efflux pumps
that chemosensitizes cells expressing Cdr1p to fluconazole (Niimi
et al., 2012). The chemosensitizer was identified, by screening
a D-octapeptide combinatorial library for surface-active efflux
inhibitors that are not substrates of multidrug efflux pumps.
The study identified RC21v3, a potent, stereospecific, surface
active, high-affinity inhibitor that interacts with the extracel-
lular surface of Cdr1p. Specific targeting of Cdr1p by RC21v3
was confirmed by isolation of spontaneous chemosensitization-
resistant suppressor mutants. Notably, the suppressor mutations
introduced a positive charge beside, or within ECL1, 3, 4, and 6
of Cdr1p or an aromatic residue near the extracytoplasmic end
of TMS5.
Intracellular loops
Fungal ABC transporters belonging to PDR sub-family gener-
ally possess peculiar arrangement of ICLs compared to those
belonging to MDR type of ABC transporters sub-family. Both the
ICLs of each TMD of MDR transporters are large and compa-
rable in size while PDR transporters generally possess one large
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and one small ICL in each TMD (Figure 2). ICL1 and ICL3 from
PDR transporters are comparatively longer in length while ICL 2
and 4 are of shorter length (Lamping et al., 2010). Structure of
MDR transporters from bacteria and higher eukaryotes reveals
that each TMD contain two ICLs which mediate the commu-
nication between NBDs and TMDs through specific coupling
helices which interact with Q-loops of NBDs and communicate
the conformational changes occurring during ATP hydrolysis to
TMDs leading to substrate transport (Ananthaswamy et al., 2010;
Lamping et al., 2010).
Recent, biochemical studies have provided evidence of ICLs
as communication link between NBDs and TMDs of Pdr5p. For
example, drug sensitive phenotype due to point mutations in
TMS in Pdr5p is suppressed by mutation in N-NBD possibly
by inter-domain communication through ICL1 (Sauna et al.,
2008). Point mutation of conserved residue in ICL2 of Pdr5p
is also able to restore the drug sensitive phenotype of mutants
from Q Loop region of N-NBD (Downes et al., 2013). Similarly
A1352M substitution in ICL4 in Pdr5p affects the drug-efflux
activity and is shown to be involved in interdomain cross-talk
(Guo et al., 2012). Mutations and cysteine cross-linking stud-
ies in ICL regions in MDR type ABC transporter Yor1p from
S. cerevisiae show that ICLs play role in protein folding and
membrane localization and in addition also act as a transmis-
sion interface between NBDs and TMDs, a situation analogous
to ABC proteins of higher eukaryotes (Pagant et al., 2008, 2010).
Suppressor mutations, which correct the drug sensitive pheno-
type in Yor1p, seem to restore the inter-domain communications
by the mechanisms different from those observed due to origi-
nal mutations (Pagant et al., 2008, 2010). Considering the clinical
importance of Cdr1p, detailed knowledge of transmission inter-
face and intra-domain communication is essential in designing
inhibitors/modulators of the transporter. However, this aspect
remains to be examined. The ECLs and ICLs which are inter-
connecting TMSs are very important with regard to interdomain
communication and thus have significant role in drug transport.
The work so far has not yet justified their role to fullest and awaits
more analysis.
ABC PROTEINS AS PHOSPHOLIPIDS TRANSLOCATORS
Several indirect lines of evidence suggest that fungal ABC trans-
porters such as the S. cerevisiae proteins Pdr5p and Yor1p and
the C. albicans proteins Cdr1p-Cdr4p can translocate fluorescent
glycerophospholipid analogs across membranes (Decottignies
et al., 1998; Smriti et al., 2002). By employing fluorescent
7-nitrobenz-2-oxa-1, 3-diazol-4-yl (NBD)-tagged phospholipid
analogs, it is demonstrated that Cdr1p and its other homologs,
Cdr2p and Cdr3p, behave as general phospholipid translocators.
Interestingly, CDR1 and CDR2, whose overexpression leads to
azole resistance in C. albicans, elicit in-to-out transbilayer phos-
pholipid movement (floppase activity), while Cdr3p, which is
not involved in drug resistance, carries out-to-in translocation
(flippase activity) of phospholipids between the two monolay-
ers of plasma membrane (Smriti et al., 2002). The phospholipid
translocation mediated by Cdr1p, Cdr2p, and Cdr3p is distin-
guishable on the basis of their sensitivities to different inhibitors.
The lipid translocation activity of Cdr1p was also confirmed by
exploiting a purified Cdr1p reconstitution into membrane vesi-
cles. It is shown that the ATP-driven transporter Cdr1p is capable
of translocating different fluorescently modified glycerophospho-
lipids between leaflets of the vesicle membrane. Notwithstanding
the role of some of the Cdrps in drug resistance, the study
clearly demonstrated that these ABC transporters of C. albicans
are phospholipid translocators and this function could repre-
sent one of the physiological functions of such large family of
proteins.
ABC PROTEINS CAN TRANSPORT HUMAN STEROID HORMONES
The ability of Pdr5p and Snq2p of S. cerevisiae and Cdr1p of
C. albicans to efflux steroid hormones, like β-estradiol and cor-
ticosterone suggests that human steroid hormones could also
be the substrates of these drug transporters (Mahe et al., 1996;
Krishnamurthy et al., 1998a). Notably, some of the drugs to
which Cdr1p overexpression confers resistance, reduce the efflux
of β-estradiol and corticosterone probably by mutual compe-
tition, thus implying commonality in binding site(s) between
steroids and drugs (Krishnamurthy et al., 1998a). Since multidrug
transporters of yeast can selectively mediate energy dependent
transport of human steroid hormones with high affinity and
specificity, it is very likely that these hormones are physiological
substrates of these proteins. Ergosterol-the analog of mammalian
cholesterol-is the closest molecule to steroids in yeast cells. It is
thus quite possible that these multidrug transporters, like human
Mdr1p, could be involved in the total sterol homeostasis in the
yeast cells (Kontoyiannis, 2000). In this regard, it is also perti-
nent to mention that progesterone, corticosteroid and estrogen
binding proteins in C. albicans have already been identified (Das
and Datta, 1985). The interaction of ketoconazole with corticos-
teroid binding protein has also been observed (Stover et al., 1983).
Additionally, the upregulation of CDR1 transcription by steroid
hormones and recent identification of steroid responsive region
in its promoter do strongly point to a possible link between the
steroid response cascade and multidrug resistance in C. albicans
(Krishnamurthy et al., 1998b).
MFS PROTEINS IN CANDIDA
The major facilitator superfamily (MFS) proteins are another
class of major drug transporters which are involved in the devel-
opment of multidrug resistance in yeasts. MFS transporters, like
ABC transporters, belong to a large superfamily of membrane
proteins from bacteria to higher eukaryotes which include sym-
porters, antiporters, and uniporters of various substrates (Marger
and Saier, 1993) (Figure 1). The MFS proteins are secondary
active transporters which utilize the electrochemical gradient of
protons to drive transport of various substrates against concen-
tration gradient across the membrane (Ben-Yaacov et al., 1994).
The genome wide inventory revealed that C. albicans genome has
95 putative MFS proteins that clustered into 17 families (Gaur
et al., 2008). Out of all MFS proteins, only CaMdr1p is known to
extrude drugs, where its overexpression has been linked to azole
resistance (Kohli et al., 2001). CaMdr1p over expression is linked
to an emergence of resistance to several unrelated drugs e.g.,
fluconazole, 4-nitroquinoline–N-oxide, cycloheximide, benomyl,
methotrexate and cerulenin (Figure 1) (Ben-Yaacov et al., 1994;
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Gupta et al., 1998; Prasad and Kapoor, 2005). The expression of
CaMDR1 in C. albicans gets enhanced by benomyl, methotrexate
and several other unrelated drugs, and was more pronounced in
some of the azole resistant clinical isolates (Gupta et al., 1998).
This confirms that over-expression of MDR1 gene directly relates
to azole resistance in clinical isolates of C. albicans (Gupta et al.,
1998). Another MFS transporter, FLU1 which is implicated in
mycophenolic acid resistance is also characterized. However, no
clinical relevance of this drug transporter has been reported
so far.
MFS consists of at least six separate families (Paulsen et al.,
1996). On the basis of hydropathy and phylogenetic analysis the
drug efflux MFS proteins are divided into two distinct types; first,
Drug: H+ Antiporter-1 (DHA1), consisting of 12 TMSs and the
second is called Drug: H+ Antiporter-2 (DHA2) that contains
14 TMSs. The CaMdr1p is a 564 amino acid protein of C. albi-
cans that belongs to the DHA1 (drug–proton antiporter) family,
which effluxes drugs in exchange with one or more H+ with a
substrate molecule (Paulsen and Skurray, 1993). It is character-
ized by two structural units of six TMS-α-helical segments, linked
by a cytoplasmic loop. Six TMSs are interconnected by ECLs and
ICLs (Figure 5).
STRUCTURE AND FUNCTION STUDIES IN CaMdr1p
In contrast to ABC drug transporter, the structure-function rela-
tionship of MFS proteins has not been analyzed in detail. There
are, however, some reports to suggest that the N-terminal halves
of different major facilitator families share greater similarities
than their C-terminal halves, which suggests that C-terminal
regions are involved in substrate recognition, and N-terminal
regions are involved in proton translocation (Saier and Reizer,
1991). Additionally, the MFS drug antiporter proteins possess
many conserved residues scattered throughout the length of the
protein, for example, motifs A and B are conserved through-
out the MFS, while motif “C” is found only in 12 and 14-TMS
subfamilies (Paulsen et al., 1996).
The bacterial MFS drug/H+antiporters, which have a unique
antiporter motif, also called motif “C” [G(X8)G(X3)GP(X2)GG],
is necessary for the drug/H+antiporter activity (Ginn et al.,
2000). Independent of the substrate promiscuity of the antiporter,
the antiporter motif in the predicted TMS5 is conserved in all
of the functionally related subgroups in bacteria and plants.
However, based on sequence homology, CaMdr1p is a putative
proton antiporter of C. albicans, with an antiporter motif in
TMS5 [G(×6)G(×3)GP(×2)GP(×2)G]) as depicted in Figure 5.
Structural and functional analyses of CaMdr1p have indicated
that amino acid residues located in TMS5 are critical for
drug/proton transport activity (Figure 6). The clustering of sev-
eral important residues including those of motif “C” which par-
ticipate in substrate specificity has been observed on one face of
the helix (Pasrija et al., 2007).
RATIONAL MUTATIONAL ANALYSIS
Site-directed mutational strategies rely on conservation of
residues in a multiple sequence alignment (MSA). The conser-
vation of a residue is calculated from the amino acid frequency
FIGURE 5 | (A) Predicted topology of the CaMdr1p with 12 transmembrane
segments. The amino and carboxyl terminals of protein are indicated. Six
extracellular loops (ECL1-6) and five intracellular loops (ICL1-5) are
indicated. Two homologous halves are connected by a central cytoplasmic
loop (CCL) or ICL3. The TMS5 is colored dark and magnified to show the
amino acid residues of TMS5. (B) Alignment of the protein sequences of
the C. albicans antiporter CaMdr1p TMS5 with the other fungal and
bacterial drug antiporters, showing the presence of the unique and
conserved antiporter motif or motif C. The amino acid sequence of TMS5
of CaMdr1p is boxed. The sequence of the antiporter motif is written for
comparison, where X can be any amino acid. Residues conserved in all
the MFS transporters that are part of the motif are highlighted in gray,
whereas residues conserved only in fungal MFS that were found critical
for the activity are highlighted in black.
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distribution in the corresponding column of a MSA. However,
the physicochemical conservation is not necessarily responsible
for a protein’s structure and function but could reflect a more
general function such as membrane localization. Thus, conser-
vation alone is not sufficient to distinguish between residues
responsible for the protein function and membrane localiza-
tion. Membrane proteins differ from soluble proteins because
of their inter-TM hydrophilic and TM hydrophobic propen-
sities, which have allowed the development of efficient mem-
brane protein TM prediction methods and of membrane protein
specific substitution matrices. Recent study employed a mem-
brane environment based computational approach to predict
the functionally critical residues of CaMdr1p. For this, DHA1
(antiporters) family was contrasted with sugar porter family (SP)
(symporters) to identify residues selectively conserved in DHA1
family vis-à-vis the SP family. The residues with highest cumu-
lative relative entropy (CRE) were short-listed for analysis and
were predicted to impart functional specificity to the DHA1
members. The functional relevance of these high-CRE scoring
residues of CaMdr1p was evaluated by employing site directed
mutagenesis. However, only those positions were mutated to ala-
nine or leucine wherein the CaMdr1p residue matched with the
most frequent amino acid at a particular alignment position of
DHA1members. Most of the mutant variants displayed com-
plete drug susceptibility while few were selectively suscepti-
ble to tested drugs (Figure 6). The enhanced susceptibility of
these mutant variants was corroborated with abrogated efflux
of substrates rather than poor expression or surface localiza-
tion. Since the prediction was based on entire DHA1 family,
this strategy, not only identified critical residues of CaMdr1p,
but also accurately predicted and validated family-wide-function
residues for this entire subfamily of antiporters (Kapoor et al.,
2010).
INTERDOMAIN COMMUNICATION
Several members of MFS proteins including fungal drug-proton
antiporter (DHA1) family (Saier et al., 2006) possess a central
cytoplasmic loop (CCL), large enough to form a cytosolic domain
(Weinglass and Kaback, 2000; Monden et al., 2001; Xu et al.,
2010). The helices in this domain are rich in non-polar amino
acids, which impart considerable amphipathicity to the loop for
establishing contacts with the plasmamembrane (Xu et al., 2010).
The CCL connecting TMDs plays an important functional role
in several MFS proteins. For example, the CCL of LacY (lactose
permease of Escherichia coli) transporter (Weinglass and Kaback,
2000), Dtr1p (di-tyrosine transporter) of S. cerevisiae (Morishita
and Engebrecht, 2008), human RFC1 (reduced folate carrier)
(Sadlish et al., 2002) and hPEPT1 (intestinal di-/tri-peptide trans-
porter) (Xu et al., 2010) are necessary for either their efficient
membrane insertion, proper maturation, expression or function.
In human GLUT1 (Glucose transporter 1), the conformational
changes within TMHs induced by the initiation of efflux activity is
shown to be communicated through CCL of the protein (Monden
et al., 2001).
FIGURE 6 | A list of residues from CaMdr1p that upon substitution gave a phenotype. TS, susceptible to all drugs; SS, selectively susceptible; ECL,
extracellular loop; TMS, transmembrane segments; ICL, intracellular loops; CCL, central cytoplasmic loop.
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In a recent study, to evaluate the role of ICL3 or CCL of
Mdr1 protein of Candida, a mutational strategy was employed
to the entire stretch of amino acid residues of the loop (Mandal
et al., 2012). The two sets of mutant variants of CaMdr1p were
constructed. One group of variants included progressive nine
deletants of different stretches of 6–7 residues and the other group
included variants where respective deletions were restored with
hexa- or hepta-alanine. The data clearly showed that most of the
deletion and substitution of ICL3 sequence stretches resulted in
non-functional protein variants of CaMdr1p that totally elimi-
nated their ability to confer multidrug resistance and substrate
efflux. Additionally, the progressive deletion and its restoration
lead to change in protein conformation and surface charge distri-
bution that was evident from the accessibility of protease diges-
tion of variants resulting in multiple tryptic fragments. A close
examination of the CCL sequence reveals that the N-terminal
half of the loop mainly contains positively charged amino acid
residues, whereas the C-terminal half contains negatively charged
amino acids. The replacement of most of the positively charged
side-chain mutants in N-terminal half of the loop with alanine
completely eliminated their ability to tolerate drugs (Figure 6).
Together, the study on ICL3 of CaMdr1p not only highlights the
critical role of CCL in fungal MFS belonging to DHA1 family in
drug transport but also shows that the large inter-domain central
ICL3 connecting the two TMDs is an essential structural element
of protein.
CONCLUDING REMARKS
Both ABC and MFS transporters belong to two big super fam-
ilies of proteins and several of them have also evolved as drug
transporters. Interestingly, though they differ in terms of energy
coupling to drug transport, (ABC proteins power drug export
by directly hydrolyzing ATP, the MFS transporters employ elec-
trochemical gradient of protons to active drug export), the
promiscuity with regard to their ability to transport variety of
structurally unrelated compounds, of the two families of trans-
porters is most common striking feature. This promiscuity of
such proteins makes it a big challenge in dissecting their struc-
ture and function. From the recent studies, it is evident that
lot of efforts are devoted in resolving the mechanisms of drug
transport. It is confirmed that TMSs of these transporters har-
bors drug binding sites and critical amino acid residues align and
make up a large drug binding pocket which can accommodate
diverse compounds to export. The challenge lies in dissecting par-
ticipation of important residues responsible for single or select
drug transport. UnlikeMFS transporetrs, several ABC drug trans-
porters are phospholipid translocators which may reflect their
normal physiological function. But understanding how phospho-
lipids and drug are transported by these proteins is a challenge.
Nonetheless, resolving such issues will pave the way in ratio-
nally designing inhibitors/modulators for making drug exporters
transport incompetent so that they could chemosensitize the drug
resistant cells.
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